Cargando…

Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications

INTRODUCTION: Glucagon-like peptide-1 (GLP-1) has been the focus of considerable research activity in the treatment of type 2 diabetes mellitus (T2DM) because the incretin effect is significantly reduced or absent in individuals with T2DM. Thus, pharmacologic efforts to develop medications that mimi...

Descripción completa

Detalles Bibliográficos
Autores principales: Unger, Jeffrey R., Parkin, Christopher G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare Communications 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3124643/
https://www.ncbi.nlm.nih.gov/pubmed/22127767
http://dx.doi.org/10.1007/s13300-010-0013-5